Keloid Scars: The Honest Limits, Before Anything Else

Keloids happen when the skin over-produces collagen during healing, though exactly why this happens in some people and not others is not fully understood. What is clear is that keloid-forming skin behaves differently: it produces far more collagen than normal healing skin, and the cells involved persist for longer than they should.

Keloids are well-evidenced as more common in darker skin tones, including in a UK-specific study of over 230,000 people, which found excessive scarring in 2.4% of Black, 1.1% of Asian and 0.4% of White participants. One professional reference has, however, more recently disputed how strong this ethnicity link really is, citing weak epidemiological evidence, so while the association is well-documented across multiple sources, it is not treated here as beyond debate.

Family history is a genuinely unsettled figure, and we won’t pretend otherwise. One source puts a family history of keloids at 5–10% of European patients; another puts it at around half of all patients. These numbers do not agree, and rather than quote one as fact, the honest position is that a family link exists but its true frequency is not well pinned down.

Surgery alone very often fails. Removing a keloid by excision on its own has a recurrence rate of 45–100%, and the British Association of Dermatologists is blunt about it: surgery “is not usually recommended because it’s likely to grow back bigger.” This is the single clearest fact in this whole picture, and it is why excision is never offered here as a standalone treatment.

No single treatment reliably works, and keloids often come back regardless of what is used. The British Association of Dermatologists’ own position is that “there is currently no evidence that any single form of treatment is better than another and keloids often regrow in the same place.” Even steroid injections (the most commonly used first-line treatment) see up to 50% of keloids grow back. Combination approaches (excision paired with radiotherapy, or laser paired with steroid injections) have shown meaningfully lower recurrence in the literature, in the region of 12–14%, but head-to-head evidence comparing these combinations directly is still lacking.

A “keloid” is occasionally something more serious. A rare cancer called dermatofibrosarcoma protuberans (DFSP) can look almost identical to a keloid, and case reports describe it being misdiagnosed as one. The features that should prompt a closer look rather than an assumption: a scar that is new in later adult life without an obvious preceding injury, one that is painful, bleeding or ulcerating, or one that keeps growing despite treatment already tried. Biopsy resolves the uncertainty; this is exactly why assessment matters before treatment, not after.

Some treatments carry their own risks. Cryotherapy can cause permanent loss of skin pigment: a particular concern in the darker skin tones most prone to keloids in the first place. Steroid injections can thin and pale the skin around the treated area. Radiotherapy, used occasionally after surgery, carries a small risk of skin cancer itself and is used sparingly for that reason.

None of this means nothing can be done. It means the honest starting point is realistic: treatment can often flatten a keloid, reduce itching and improve how it looks, but there is no guaranteed cure, and recurrence is a genuine possibility whatever approach is used.